Mereo BioPharma Group plc American Depositary Shares (MREO)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

In fiscal 2025, the year ended 2025-12-31, Mereo reported revenue of $500,000 and a net loss of $41.9 million, or diluted EPS of -$0.05. In fiscal 2024, the year ended 2024-12-31, revenue was not reported and net loss was $43.3 million. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $7.0 million, or -$0.01 per diluted share, with no revenue reported. The company has not earned a profit in each of the last four years, which is why the computed Lynch category is none. Trailing free cash flow is -$25.6 million, and FairStock calculates an FCF yield of -50.9%, so cash burn is enormous relative to the $50.4 million market cap at the close on 2026-10-13. FairStock also calculates P/B of 1.78, P/E of -1.60, ROE of -67.85%, Piotroski F-Score of 1/9, and Altman Z-Score of -15.72. Those are not the marks of a durable, profitable franchise. Low debt-to-equity of 0.04 is a relative strength, but it does not offset operating losses. The pipeline—Setrusumab, Alvelestat, and Vantictumab—could create value if approved, but there are no marketed products and no visible moat today. At $0.32, the price is far below the 52-week high of $2.37, but low price is not the same as cheap. Graham would want proven earnings and a margin of safety; Buffett would want a durable competitive advantage. Here I see a speculative development-stage biotech, not a value investment.

In plain English: Mereo BioPharma is a small biotech developing rare-disease medicines. It has almost no revenue, loses money, and burns cash, so the business looks weak today. At $0.32, the price is not supported by profits or meaningful sales; it looks speculative rather than cheap based on its current numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer